Skip to main content

Table 1 Response rates to anti-PD-1 and overall survival in NSCLC by study

From: PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

Study

Histology

Treatment

# patients

ORR (%)

Median response duration (months)

OS (months)

Nivolumab

 Gettinger et al. [11]a

All

Nivolumab 3 mg/kg q2wks

37

24.3

17

14.9

Nivolumab 10 mg/kg q2wks

59

20.3

19.1

9.2

 Rizvi et al. [13] (CHECKMATE 063)

Squamous

Nivolumab 3 mg/kg q2wks

117

14.5

Not reached

8.2

 Brahmer et al. [14] (CHECKMATE 017)

Squamous

Nivolumab 3 mg/kg q2wks

135

20

Not reached

9.2

Docetaxel 75 mg/m2 q3wks

137

9

8.4

6

 Borghaei et al. [15] (CHECKMATE 057)

Non-squamous

Nivolumab 3 mg/kg q2wks

292

19

17.2

12.2

Docetaxel 75 mg/m2 q3wks

290

12

5.6

9.4

 Bauer et al. [55]

All

Nivolumab 3 mg/kg q 2wks

51

13.7

Not reported

Not reported

Pembrolizumab

 Garon et al. [16] (KEYNOTE 001)

All

Pembrolizumab 2 mg/kg q3wks

6

33.3

12.5

9.3 (prior therapy)

Pembrolizumab 10 mg/kg q3wks

287

19.2

16.2 (no prior therapy)

Pembrolizumab 10 mg/kg q2wks

202

19.3

 Herbst et al. [17] (KEYNOTE 010)

All

Pembrolizumab 2 mg/kg q3wks

344

18

Not reached

10.4

Pembrolizumab 10 mg/kg q3wks

346

18.5

Not reached

12.7

Docetaxel 75 mg/m2 q3wks

343

9.3

6

8.5

  1. aCohorts receiving doses lower than 3 mg/kg were omitted from the table due to low response rates